U.S. markets close in 1 hour 12 minutes
  • S&P 500

    3,832.88
    -37.41 (-0.97%)
     
  • Dow 30

    31,388.22
    -3.30 (-0.01%)
     
  • Nasdaq

    13,023.11
    -335.68 (-2.51%)
     
  • Russell 2000

    2,211.44
    -20.07 (-0.90%)
     
  • Crude Oil

    61.40
    +1.65 (+2.76%)
     
  • Gold

    1,713.50
    -20.10 (-1.16%)
     
  • Silver

    26.28
    -0.60 (-2.23%)
     
  • EUR/USD

    1.2071
    -0.0016 (-0.13%)
     
  • 10-Yr Bond

    1.4700
    +0.0550 (+3.89%)
     
  • GBP/USD

    1.3958
    +0.0002 (+0.01%)
     
  • USD/JPY

    106.9500
    +0.2400 (+0.22%)
     
  • BTC-USD

    50,863.39
    +3,122.28 (+6.54%)
     
  • CMC Crypto 200

    1,019.22
    +31.13 (+3.15%)
     
  • FTSE 100

    6,675.47
    +61.72 (+0.93%)
     
  • Nikkei 225

    29,559.10
    +150.93 (+0.51%)
     

Phathom Pharmaceuticals to Participate at Upcoming Investor Healthcare Conferences

  • Oops!
    Something went wrong.
    Please try again later.
Phathom Pharmaceuticals
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

FLORHAM PARK, N.J., Nov. 27, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of the management team will participate at two upcoming virtual investor conferences in December, including:

  • Evercore ISI 3rd Annual HealthCONx Conference
    Date: December 1, 2020
    Live Presentation Time: 10:55 am ET

  • Piper Sandler 32nd Annual Virtual Healthcare Conference
    Date: December 2, 2020
    Pre-recorded presentation available online

Executive management will also participate in one-on-one meetings during the duration of the conferences.

To access the live webcast and archived recordings for each presentation, visit the News & Events section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. Recordings will be available for 30 days following each event.

About Phathom
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. Phathom has in-licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a novel potassium competitive acid blocker (P-CAB) in late-stage development for the treatment of acid-related disorders. For more information about Phathom, visit the Company’s website at www.phathompharma.com or follow the Company on social media: LinkedIn at www.linkedin.com/company/phathompharma and Twitter @PhathomPharma.

CONTACTS

Media Contact:
Nick Benedetto
1-877-742-8466
media@phathompharma.com

Investor Contact:
Todd Branning
1-877-742-8466
ir@phathompharma.com